Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials

Tiantian Guo; Yue Zhou; Fei Liang; Zezhou Wang; Vincent Bourbonne; Lukas Käsmann; Nora Sundahl; Abraham Jing-Ching Wu; Jianjiao Ni; Zhengfei Zhu

doi:10.1002/cac2.12512

Cancer Communications ›› 2024, Vol. 44 ›› Issue (2) :278 -281. DOI: 10.1002/cac2.12512

LETTER TO THE EDITOR

Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials

Tiantian Guo ¹^,²^,³^,⁴
, Yue Zhou ¹^,²^,³^,⁴
, Fei Liang ⁵
, Zezhou Wang ²^,⁶
, Vincent Bourbonne ⁷
, Lukas Käsmann ⁸
, Nora Sundahl ⁹
, Abraham Jing-Ching Wu ¹⁰
, Jianjiao Ni ¹^,²^,³^,⁴^,^†
, Zhengfei Zhu ¹^,²^,³^,⁴^,¹¹^,^†

Author information +

¹. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China

². Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P. R. China

³. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, P. R. China

⁴. Shanghai Key Laboratory of Radiation Oncology, Shanghai, P. R. China

⁵. Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, P. R. China

⁶. Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, P. R. China

⁷. Radiation Oncology Department, University Hospital, Brest, France

⁸. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

⁹. Department of Radiation Oncology, AZ Groeninge, Kortrijk, Belgium

¹⁰. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

¹¹. Institute of Thoracic Oncology, Fudan University, Shanghai, P. R. China

nijianjiao8@sina.com

fuscczzf@163.com

Show less

History +

PDF

Cite this article

Download citation ▾

Tiantian Guo, Yue Zhou, Fei Liang, Zezhou Wang, Vincent Bourbonne, Lukas Käsmann, Nora Sundahl, Abraham Jing-Ching Wu, Jianjiao Ni, Zhengfei Zhu. Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. Cancer Communications, 2024, 44(2): 278-281 DOI:10.1002/cac2.12512

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	ErnaniV, Stinchcombe TE. Management of Brain Metastases in Non-Small-Cell Lung Cancer. J Oncol Pract. 2019;15(11):563–570.

[2]	HendriksLEL, HenonC, AuclinE, Mezquita L, FerraraR, Audigier-ValetteC, et al. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. J Thorac Oncol. 2019;14(7):1244–1254.

[3]	DudnikE, Moskovitz M, DaherS, ShamaiS, Hanovich E, GrubsteinA, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. Lung Cancer. 2018;126:217–223.

[4]	ArbourKC, Mezquita L, LongN, RizviH, AuclinE, NiA, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(28):2872–2878.

[5]	MountziosG, de Toma A, EconomopoulouP, FriedlaenderA, BaniniM, Lo RussoG, et al. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021;22(2):e180–e192.

[6]

WestH, McCleod M, HusseinM, MorabitoA, Rittmeyer A, ConterHJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–937.

[7]	JotteR, Cappuzzo F, VynnychenkoI, StroyakovskiyD, Rodríguez-Abreu D, HusseinM, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol. 2020;15(8):1351–1360.

[8]	SocinskiMA, JotteRM, CappuzzoF, Orlandi F, StroyakovskiyD, NogamiN, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.

[9]	ChenH, FengY, ZhouY, Tao Y, TangL, ShiY. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;71(12):3071–3085.

[10]	GuoT, ChuL, ChuX, YangX, LiY, ZhouY, et al. Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Transl Lung Cancer Res. 2022;11(2):173–187.